Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical activity and tolerability of a
combination of obinutuzumab plus venetoclax in patients with relapsed or refractory diffuse
large B-cell lymphoma.